↓ Skip to main content

Cochrane Database of Systematic Reviews

Methotrexate for treating rheumatoid arthritis

Overview of attention for article published in Cochrane database of systematic reviews, June 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news
1 news outlet
policy
1 policy source
twitter
9 tweeters
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
180 Dimensions

Readers on

mendeley
472 Mendeley
Title
Methotrexate for treating rheumatoid arthritis
Published in
Cochrane database of systematic reviews, June 2014
DOI 10.1002/14651858.cd000957.pub2
Pubmed ID
Authors

Maria Angeles Lopez-Olivo, Harish R Siddhanamatha, Beverley Shea, Peter Tugwell, George A Wells, Maria E Suarez-Almazor

Abstract

Methotrexate is a folic acid antagonist widely used for the treatment of neoplastic disorders. Methotrexate inhibits the synthesis of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins by binding to dihydrofolate reductase. Currently, methotrexate is among the most commonly used drugs for the treatment of rheumatoid arthritis (RA). This is an update of the previous Cochrane systematic review published in 1997.

Twitter Demographics

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 472 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 3 <1%
Switzerland 1 <1%
Brazil 1 <1%
Pakistan 1 <1%
South Africa 1 <1%
Spain 1 <1%
Unknown 464 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 69 15%
Researcher 53 11%
Student > Bachelor 51 11%
Student > Ph. D. Student 48 10%
Student > Postgraduate 32 7%
Other 87 18%
Unknown 132 28%
Readers by discipline Count As %
Medicine and Dentistry 178 38%
Nursing and Health Professions 29 6%
Pharmacology, Toxicology and Pharmaceutical Science 28 6%
Biochemistry, Genetics and Molecular Biology 19 4%
Agricultural and Biological Sciences 16 3%
Other 55 12%
Unknown 147 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 June 2022.
All research outputs
#1,386,679
of 23,237,082 outputs
Outputs from Cochrane database of systematic reviews
#3,153
of 12,404 outputs
Outputs of similar age
#14,570
of 230,230 outputs
Outputs of similar age from Cochrane database of systematic reviews
#55
of 233 outputs
Altmetric has tracked 23,237,082 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,404 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 32.7. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 230,230 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 233 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.